Upcoming Allied Market Research
T-cell Therapy Market

T-Cell therapy Market

- Global Opportunity Analysis and Industry Forecast, 2022-2029

Report Code: A10528
Pages: NA
Nov 2022 | 611 Views
Author(s) : NA
Tables: NA
Charts: NA
  • Formats*:

  • Single User License, Five User
    License & Enterprise User License

  • Data Pack Excel License

  • It comes with the additional cost
    of $2500.00 contact sales.



Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the T-cell Therapy Market

Request Now !

T-Cell therapy MarketOutlook 2027

T-cell therapy is a form of immunotherapy that uses specially altered T cells — a part of the immune system — to fight cancer. A sample of a patient's T cells are collected from the blood, then modified to produce special structures called chimeric antigen receptors (CARs) on their surface. When these T cells are reinfused into the patient, the new receptors enable them to latch onto a specific antigen on the patient's tumor cells and kill them.Currently, T-cell therapy is FDA approved as standard of care for some forms of aggressive, relapsed or refractory non-Hodgkin lymphoma, including diffuse large B cell lymphoma, primary mediastinal B-cell lymphoma, high grade B-cell lymphoma, transformed follicular lymphoma, and mantle cell lymphoma. In addition, T-cell therapy is approved for patients with relapsed or refractory acute lymphoblastic leukemia up to age 25. There are also many clinical trials of T-cell therapy for other types of blood cancer and solid tumors.

T-Cell therapy Marketscope and structure analysis:

Report Metric


Market size available for years


Base year considered


Forecast period


Forecast unit

Value (USD)

Segments covered

Type, Type of Imaging, End User,and Region

Regions covered

North America (the U.S. and Canada), Europe (Germany, the UK, France, and rest of Europe), Asia-Pacific (China, Japan, India, and rest of Asia-Pacific), Latin America (Brazil, Mexico, and rest of LATAM), and the Middle East and Africa

Companies covered

Juno Therapeutics, Kite Pharma, Adaptimmune, Tmunity Therapeutics, GigaGen, Tessa, Poseida Therapeutics, and B-MoGen Biotechnologies.


COVID-19 scenarioanalysis:

Pharmaceutical and biotechnological companies together with governments around the globe are working to combat with the COVID-19 outbreak, from supporting the development of vaccines to schedule for medicines supply chain challenges. Furthermore, there are around 115 vaccine candidates and other 155 molecules that are kept in the R&D pipeline in the coming years. Moreover, commonly used drugs, such as hydroxychloroquine, have witnessedhugeboost in demand for the management of COVID-19. Increase in demand for drugs had presented huge opportunity for manufacturers of COVID-19 management drugs, as many developed countries are short of these drugs. Attributedto the demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is anticipated to witness a substantial growth in the next few years.

Top impacting factors: Market scenario analysis, trends, drivers, and impact analysis

The major factor affecting the industry includesincrease inapplication of T-cell therapeutic immunity system. In addition, growth in the number of cancer patients globally would help the industry propel during the forecast period.Variation in disease patterns and the surge in awareness programs among the population are anticipated to help the industry gain traction in the next few years.Favorable reimbursement policies &strictregulations and applicability of T-cell therapies in various research centers mainly focusing on cancer treatmentare expected to boost the growth of the industry over the forecast period.

Growth in the number of products launches to boost the T-Cell therapy market

Increase in number of products launches due to high demand from the population is anticipated to propel the growth of the industry in the next few years. For instance, in July 2020, the U.S. Food and Drug Administration approved Tecartus (brexucabtagene autoleucel), a cell-based gene therapy for treatment of adult patients diagnosed with mantle cell lymphoma (MCL) who have not responded to or who have relapsed following other kinds of treatment. Tecartus, a chimeric antigen receptor (CAR) T cell therapy, is the first cell-based gene therapy approved by the FDA for the treatment of MCL.

Furthermore, in June 2019, Proteona Pte. Ltd. launched its latest ESCAPE proteogenomics assay designed specifically for Chimeric Antigen Receptor (CAR)T cell characterization. This is the first commercial product designed to characterize both RNA and protein expression levels across thousands of single CART cells. Through the use of simultaneous gene and protein expression analysis, the ESCAPE CAR T assay is able to identify CAR positive cells, measure changes in cytokine expression,deeply phenotype cells through measuring the expression of 25 key cell surface proteins, and discover new gene expression patterns important for research. Together with Proteona’s state-of-the-art data analysis support, the ESCAPE CAR T assay provides rich information that can be used at all stages of the CAR T workflow from initial cell collection to post infusion patient monitoring.

Surge in number of mergers & acquisitions to propel the market

Increased mergers & acquisitions are anticipated to help the industryboost in the coming years. For instance, in November 2020, Sanofi signed a definitive agreement to acquire biopharmaceutical company, Kiadis, in a $359 million pharma acquisition deal. Under this agreement, Kiadis will use its natural killer (NK) cell-based platform to develop treatments for life-threatening diseases. This platform is based on NK-cells from “healthy donors” that have the potential to make NK-cell therapy products available quickly and economically for a potentially wider range of indications.

In October 2020, Bayer acquired Asklepios BioPharmaceutical (AskBio) to broaden its base in cell and gene therapy. As part of the acquisition deal, Bayer will own full rights to AskBio’s gene therapy platform, which includes investigational pre-clinical and clinical stage candidates for the treatment of neuromuscular, central nervous system, cardiovascular, and metabolic diseases. The platform will allow Bayer to provide treatment to patients across multiple disease areas with high unmet need.

Key segments covered:




  • Hematologic Malignancies
  • Solid Tumors

Type of Imaging

  • TCR Therapy
  • CAR T-Cell Therapy
  • TIL Therapy

End User

  • Hospitals
  • Cancer Research Institutes
  • Clinics & Ambulatory Centers
  • Others

Key benefits of the report:

  • This study presents the analytical depiction of the global T-Cell therapymarketalong with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global T-Cell therapymarket share.
  • The current market is quantitatively analyzed from 2020 to 2027 to highlight the global T-Cell therapymarket growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed global T-Cell therapymarket analysis based on competitive intensity and how the competition will take shape in coming years.

Questions answered in the market research report:

  • Which are the leading market players active in the market?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What are the projections for the future that would help in taking further strategic steps?

T-Cell therapy Market Report Highlights

Aspects Details
By Type
  • Hematologic Malignancies
  • Solid Tumors
By Type of Imaging
  • TCR Therapy
  • CAR T-Cell Therapy
  • TIL Therapy
By End User
  • Hospitals
  • Cancer Research Institutes
  • Clinics & Ambulatory Centers
  • Others
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players Juno Therapeutics,, Kite Pharma,, Adaptimmune,, Tmunity Therapeutics,, GigaGen,, Tessa,, Poseida Therapeutics,, B-MoGen Biotechnologies, Merck KGaA, TCR2 Therapeutics Inc

Loading Table Of Content...

With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace

With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast

Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts

Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)

Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : + 44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now









Purchase Full Report of
T-cell Therapy Market

Start reading.
This Report and over 18,833+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Enterprise

  • $9,870
  • Unlimited
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Library

  • $ 999
    Per User/ Per month/ Billed annually
  • Published Content
  • Company Profiles
  • Newly Added Content Access
  • 10 PDF
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD


Why Allied Market Research?


Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction


On-demand customization of scope of the report to exactly meet your needs


Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction


On-demand customization of scope of the report to exactly meet your needs


Targeted market view to provide pertinent information and save time of readers